Bill Text
Skip navigation
2prescription drug cost reporting by manufacturers, making an appropriation,
3and providing a penalty.Analysis by the Legislative Reference BureauThis bill requires certain cost reporting by manufacturers of brand-name and generic drugs. The bill requires a manufacturer to notify the Department of Health Services and the Office of the Commissioner of Insurance if it is 1) increasing the wholesale acquisition cost of a brand-name drug on the market in Wisconsin by more than 25 percent over a 24-month period; 2) intending to introduce in Wisconsin a brand-name drug that has an annual wholesale acquisition cost of $30,000 or more; 3) increasing the wholesale acquisition cost of a generic drug on the market in Wisconsin by more than 25 percent or by more than $300 during any 12-month period; or 4) intending to introduce in Wisconsin a generic drug that has an annual wholesale acquisition cost of $3,000 or more. The manufacturer must provide the notice at least 30 days before the planned date of the increase or introduction and must provide a justification including a description described in the bill. A manufacturer is also required to annually report to DHS and OCI the value of price concessions provided to each pharmacy benefit manager for each drug sold in Wisconsin for which a notice was required. The bill also requires each manufacturer of a brand-name or generic drug sold in Wisconsin to submit to DHS and OCI a report containing a description of each manufacturer-sponsored assistance program in effect during the previous year that includes the criteria for participation, the program terms, and the number of prescriptions and the total market value of assistance provided to residents of Wisconsin under the program. The manufacturer must certify the information provided in a notice or report required under the bill under penalty of perjury, and failure to provide the notice or report is subject to a forfeiture determined by DHS but not to exceed $10,000 per day past due.The bill requires DHS to publish the pricing justification information reported by manufacturers on its website. DHS must also analyze the information and publish a report on its website describing trends in drug pricing.The bill provides an additional appropriation to DHS for the purpose of administering prescription drug cost reporting by manufacturers and also authorizes 2.0 additional positions for DHS for that purpose.For further information see the state fiscal estimate, which will be printed as an appendix to this bill.The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:SB1149,11Section 1. 20.005 (3) (schedule) of the statutes: at the appropriate place,
2insert the following amounts for the purposes indicated: - See PDF for table SB1149,29Section 2. 20.435 (1) (fp) of the statutes is created to read:SB1149,2,121020.435 (1) (fp) Prescription drug cost reporting by manufacturers. Biennially,
11the amounts in the schedule to administer prescription drug cost reporting under s.
12146.901.SB1149,31Section 3. 146.901 of the statutes is created to read:SB1149,3,32146.901 Prescription drug cost reporting by manufacturers. (1)
3Definitions. In this section:SB1149,3,54(a) “Brand-name drug” means a prescription drug approved under 21 USC
5355 (b) or 42 USC 262.SB1149,3,66(b) “Generic drug” means a prescription drug approved under 21 USC 355 (j).SB1149,3,97(c) “Manufacturer” has the meaning given in s. 450.01 (12). “Manufacturer”
8does not include an entity that is engaged only in the dispensing, as defined in s.
9450.01 (7), of a brand-name drug or a generic drug.SB1149,3,1310(d) “Manufacturer-sponsored assistance program” means a program offered
11by a manufacturer or an intermediary under contract with a manufacturer through
12which a brand-name drug or a generic drug is provided to a patient at no charge or
13at a discount.SB1149,3,1414(e) “Office” means the office of the commissioner of insurance.SB1149,3,1515(f) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).SB1149,3,1916(g) “Wholesale acquisition cost” means the most recently reported
17manufacturer list or catalog price for a brand-name drug or a generic drug available
18to wholesalers or direct purchasers in the United States, before application of
19discounts, rebates, or reductions in price.SB1149,4,220(2) Price increase or introduction notice; justification report. (a) A
21manufacturer shall notify the department and the office if it is increasing the
22wholesale acquisition cost of a brand-name drug on the market in this state by more
23than 25 percent over a 24-month period or if it intends to introduce to market in
1this state a brand-name drug that has an annual wholesale acquisition cost of
2$30,000 or more.SB1149,4,73(b) A manufacturer shall notify the department and the office if it is
4increasing the wholesale acquisition cost of a generic drug on the market in this
5state by more than 25 percent or by more than $300 during any 12-month period or
6if it intends to introduce to market in this state a generic drug that has an annual
7wholesale acquisition cost of $3,000 or more.SB1149,4,128(c) The manufacturer shall provide the notice under par. (a) or (b) in writing
9at least 30 days before the planned effective date of the cost increase or drug
10introduction and shall provide a justification that includes all documents and
11research related to the manufacturer’s selection of the price increase or
12introduction price and includes a description of all of the following:SB1149,4,13131. The estimated cost-effectiveness of the drug.SB1149,4,15142. The price and effectiveness of similar drugs available in this state and the
15anticipated sales performance of the drug as compared to similar drugs.SB1149,4,18163. The impact of negotiated or mandated discounts to pharmacy benefit
17managers, insurers, and other payers of health care costs on the pricing
18determination for the drug.SB1149,4,2319(d) By March 1 annually, each manufacturer shall report to the department
20and the office the value of price concessions, expressed as a percentage of the
21wholesale acquisition cost, provided to each pharmacy benefit manager for each
22drug sold by the manufacturer in this state for which a notice is required under par.
23(a) or (b) in the previous calendar year.SB1149,5,51(3) Manufacturer-sponsored assistance programs. By March 1 annually,
2each manufacturer of a brand-name drug or generic drug sold in this state shall
3submit to the department and the office a report containing a description of each
4manufacturer-sponsored assistance program in effect during the previous calendar
5year that includes all of the following:SB1149,5,76(a) The criteria for participation in the manufacturer-sponsored assistance
7program and the manufacturer-sponsored assistance program terms.SB1149,5,98(b) The number of prescriptions provided to residents of this state under the
9manufacturer-sponsored assistance program.SB1149,5,1110(c) The total market value of assistance provided to residents of this state
11under the manufacturer-sponsored assistance program.SB1149,5,1612(4) Penalty. The manufacturer shall certify the information reported under
13sub. (2) or (3) as accurate under penalty of perjury. A manufacturer that fails to
14provide the notice or report under sub. (2) or (3) is subject to a forfeiture as
15determined by the department but not to exceed $10,000 for each day the notice or
16report is past due.SB1149,5,1817(5) Posting of report; hearing. (a) The department shall publish on its
18website the justification documentation provided under sub. (2) (c).SB1149,5,2219(b) The department shall analyze the information submitted under subs. (2)
20and (3) and publish a report on its website describing trends in drug pricing. The
21department shall conduct at least one public hearing annually on the findings of
22the report.SB1149,423Section 4. Nonstatutory provisions.SB1149,6,41(1) Prescription drug cost reporting by manufacturers. The authorized
2FTE positions for the department of health services are increased by 2.0 GPR
3positions, to be funded from the appropriation under s. 20.435 (1) (fp), for the
4purpose of administering prescription drug cost reporting under s. 146.901.SB1149,6,55(end) Down Down /2025/related/proposals/sb1149 true proposaltext /2025/related/proposals/sb1149 proposaltext/2025/REG/SB1149 proposaltext/2025/REG/SB1149 section true
PDF view
Link (Permanent link)
Bookmark this location
View toggle
Go to top of document
Search in this chapter
Search in this section
Search in this agency
Search in this chapter group
Search in this chapter
Search in this section
Cross references for section
Acts affecting this section
References to this
1970 Statutes Annotations
Appellate Court Citations
Administrative Code Index
Reference lines
Clear highlighting
- Home
- Documents
- Senate
- Assembly
- Committees
- Service Agencies
- Docs
- Options
- Help
- 2025 Biennium
- Statutes
- Admin. Rules
- Indices
- Miscellaneous
- Archives
- Home
- Bill, Rule, and Appointment Histories
- Senators
- Representatives
- Committees
- Text of Introduced Proposals
- Amendment Text
- Acts
- Veto Messages
- Enrolled Bills
- Votes
- Assembly and Senate Floor Calendars
- Schedule of Committee Activities
- Assembly and Senate Journals
- Committee Records (ROCPs)
- Legislative Rules
- All Session-Related Documents
- Subject Index to Acts
- Subject Index to Legislation
- Subject Index to Journals
- Author Index to Legislation
- Subject Index to Clearinghouse Rules
- Miscellaneous Budget Documents
- Executive Orders
- Rulings of the Chair
- Wisconsin Supreme Court Rules
- Opinions of the Attorney General
- Town Law Forms
- Law
- Districts
- Session
- Drafting Files
- Feeds
- Preferences
- Show tree
- Hide tree
- Feedback
- Help
- Home
- Senate Home
- Senators
- Committees
- Session
- Chief Clerk
- Sergeant at Arms
- Civics Education
- Human Resources
- Assembly Home
- Representatives
- Committees
- Session
- Chief Clerk
- Sergeant at Arms
- Human Resources
- Schedule
- Joint
- Senate
- Assembly
- Study
- Legislative Audit Bureau
- Legislative Council
- Legislative Fiscal Bureau
- Legislative Human Resources Office
- Legislative Reference Bureau
- Legislative Technology Services Bureau
- Menu
- »2025
- »Related Documents
- »Proposal Text
- »SB1149: Bill Text
2prescription drug cost reporting by manufacturers, making an appropriation,
3and providing a penalty.Analysis by the Legislative Reference BureauThis bill requires certain cost reporting by manufacturers of brand-name and generic drugs. The bill requires a manufacturer to notify the Department of Health Services and the Office of the Commissioner of Insurance if it is 1) increasing the wholesale acquisition cost of a brand-name drug on the market in Wisconsin by more than 25 percent over a 24-month period; 2) intending to introduce in Wisconsin a brand-name drug that has an annual wholesale acquisition cost of $30,000 or more; 3) increasing the wholesale acquisition cost of a generic drug on the market in Wisconsin by more than 25 percent or by more than $300 during any 12-month period; or 4) intending to introduce in Wisconsin a generic drug that has an annual wholesale acquisition cost of $3,000 or more. The manufacturer must provide the notice at least 30 days before the planned date of the increase or introduction and must provide a justification including a description described in the bill. A manufacturer is also required to annually report to DHS and OCI the value of price concessions provided to each pharmacy benefit manager for each drug sold in Wisconsin for which a notice was required. The bill also requires each manufacturer of a brand-name or generic drug sold in Wisconsin to submit to DHS and OCI a report containing a description of each manufacturer-sponsored assistance program in effect during the previous year that includes the criteria for participation, the program terms, and the number of prescriptions and the total market value of assistance provided to residents of Wisconsin under the program. The manufacturer must certify the information provided in a notice or report required under the bill under penalty of perjury, and failure to provide the notice or report is subject to a forfeiture determined by DHS but not to exceed $10,000 per day past due.The bill requires DHS to publish the pricing justification information reported by manufacturers on its website. DHS must also analyze the information and publish a report on its website describing trends in drug pricing.The bill provides an additional appropriation to DHS for the purpose of administering prescription drug cost reporting by manufacturers and also authorizes 2.0 additional positions for DHS for that purpose.For further information see the state fiscal estimate, which will be printed as an appendix to this bill.The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:SB1149,11Section 1. 20.005 (3) (schedule) of the statutes: at the appropriate place,
2insert the following amounts for the purposes indicated: - See PDF for table SB1149,29Section 2. 20.435 (1) (fp) of the statutes is created to read:SB1149,2,121020.435 (1) (fp) Prescription drug cost reporting by manufacturers. Biennially,
11the amounts in the schedule to administer prescription drug cost reporting under s.
12146.901.SB1149,31Section 3. 146.901 of the statutes is created to read:SB1149,3,32146.901 Prescription drug cost reporting by manufacturers. (1)
3Definitions. In this section:SB1149,3,54(a) “Brand-name drug” means a prescription drug approved under 21 USC
5355 (b) or 42 USC 262.SB1149,3,66(b) “Generic drug” means a prescription drug approved under 21 USC 355 (j).SB1149,3,97(c) “Manufacturer” has the meaning given in s. 450.01 (12). “Manufacturer”
8does not include an entity that is engaged only in the dispensing, as defined in s.
9450.01 (7), of a brand-name drug or a generic drug.SB1149,3,1310(d) “Manufacturer-sponsored assistance program” means a program offered
11by a manufacturer or an intermediary under contract with a manufacturer through
12which a brand-name drug or a generic drug is provided to a patient at no charge or
13at a discount.SB1149,3,1414(e) “Office” means the office of the commissioner of insurance.SB1149,3,1515(f) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).SB1149,3,1916(g) “Wholesale acquisition cost” means the most recently reported
17manufacturer list or catalog price for a brand-name drug or a generic drug available
18to wholesalers or direct purchasers in the United States, before application of
19discounts, rebates, or reductions in price.SB1149,4,220(2) Price increase or introduction notice; justification report. (a) A
21manufacturer shall notify the department and the office if it is increasing the
22wholesale acquisition cost of a brand-name drug on the market in this state by more
23than 25 percent over a 24-month period or if it intends to introduce to market in
1this state a brand-name drug that has an annual wholesale acquisition cost of
2$30,000 or more.SB1149,4,73(b) A manufacturer shall notify the department and the office if it is
4increasing the wholesale acquisition cost of a generic drug on the market in this
5state by more than 25 percent or by more than $300 during any 12-month period or
6if it intends to introduce to market in this state a generic drug that has an annual
7wholesale acquisition cost of $3,000 or more.SB1149,4,128(c) The manufacturer shall provide the notice under par. (a) or (b) in writing
9at least 30 days before the planned effective date of the cost increase or drug
10introduction and shall provide a justification that includes all documents and
11research related to the manufacturer’s selection of the price increase or
12introduction price and includes a description of all of the following:SB1149,4,13131. The estimated cost-effectiveness of the drug.SB1149,4,15142. The price and effectiveness of similar drugs available in this state and the
15anticipated sales performance of the drug as compared to similar drugs.SB1149,4,18163. The impact of negotiated or mandated discounts to pharmacy benefit
17managers, insurers, and other payers of health care costs on the pricing
18determination for the drug.SB1149,4,2319(d) By March 1 annually, each manufacturer shall report to the department
20and the office the value of price concessions, expressed as a percentage of the
21wholesale acquisition cost, provided to each pharmacy benefit manager for each
22drug sold by the manufacturer in this state for which a notice is required under par.
23(a) or (b) in the previous calendar year.SB1149,5,51(3) Manufacturer-sponsored assistance programs. By March 1 annually,
2each manufacturer of a brand-name drug or generic drug sold in this state shall
3submit to the department and the office a report containing a description of each
4manufacturer-sponsored assistance program in effect during the previous calendar
5year that includes all of the following:SB1149,5,76(a) The criteria for participation in the manufacturer-sponsored assistance
7program and the manufacturer-sponsored assistance program terms.SB1149,5,98(b) The number of prescriptions provided to residents of this state under the
9manufacturer-sponsored assistance program.SB1149,5,1110(c) The total market value of assistance provided to residents of this state
11under the manufacturer-sponsored assistance program.SB1149,5,1612(4) Penalty. The manufacturer shall certify the information reported under
13sub. (2) or (3) as accurate under penalty of perjury. A manufacturer that fails to
14provide the notice or report under sub. (2) or (3) is subject to a forfeiture as
15determined by the department but not to exceed $10,000 for each day the notice or
16report is past due.SB1149,5,1817(5) Posting of report; hearing. (a) The department shall publish on its
18website the justification documentation provided under sub. (2) (c).SB1149,5,2219(b) The department shall analyze the information submitted under subs. (2)
20and (3) and publish a report on its website describing trends in drug pricing. The
21department shall conduct at least one public hearing annually on the findings of
22the report.SB1149,423Section 4. Nonstatutory provisions.SB1149,6,41(1) Prescription drug cost reporting by manufacturers. The authorized
2FTE positions for the department of health services are increased by 2.0 GPR
3positions, to be funded from the appropriation under s. 20.435 (1) (fp), for the
4purpose of administering prescription drug cost reporting under s. 146.901.SB1149,6,55(end) Down Down /2025/related/proposals/sb1149 true proposaltext /2025/related/proposals/sb1149 proposaltext/2025/REG/SB1149 proposaltext/2025/REG/SB1149 section true
- Menu
- »2025
- »Related Documents
- »Proposal Text
- »SB1149: Bill Text
PDF view
Link (Permanent link)
Bookmark this location
View toggle
Go to top of document
Search in this chapter
Search in this section
Search in this agency
Search in this chapter group
Search in this chapter
Search in this section
Cross references for section
Acts affecting this section
References to this
1970 Statutes Annotations
Appellate Court Citations
Administrative Code Index
Reference lines
Clear highlighting
Official text from the Wisconsin Legislature. Formatting has been adapted for reading on Ratifi.